Parkinson’s disease (PD) |
STING pathway implicated in the onset of neuroinflammation, neurodegeneration and motor deficits in Parkin–/– mice |
N/A |
Genetic deletion of STING attenuates the loss of dopaminergic neurons and motor deficits seen in Parkin–/– mice |
Sliter et al., 2018 |
Ataxia telangiectasia (AT) |
STING drives type-I IFN induction in ATM–/– mice |
N/A |
Genetic deletion of STING reduced type-I IFN response caused by loss of ATM gene |
Hartlova et al., 2015 |
Huntington’s disease (HD) |
Increased cGAS, p-TBK1 and p-STING expression found in HdhQ111/Q111 mice |
Increased cGAS protein expression found in HD striatal neurons |
N/A |
Sharma et al., 2020 |
Multiple Sclerosis (MS) |
STING-induced type-I IFN production attenuates EAE pathology Mice lacking functional STING display attenuated EAE development |
cGAS and STING gene expression is downregulated in relapsed MS patients |
Use of STING agonist c-di-GMP delayed disease onset and severity in EAE mouse model Activating STING using antiviral therapeutic ganciclovir was able to attenuate disease progression in EAE mice |
Lemos et al., 2014; Mathur et al., 2017; Masanneck et al., 2020
|
Systemic lupus erythematosus (SLE) |
Loss of STING accelerates mortality and disease progression in Lupus prone mice (MRL-Faslpr) |
ISG inducing activity of sera derived from SLE patients is STING dependent |
N/A |
Sharma et al., 2015; Kato et al., 2018
|
Amyotrophic lateral sclerosis (ALS) |
Increased cGAS and cGAMP detected in the spinal cords of Prp-TDP-43Tg/+ mice Genetic deletion of STING in Prp-TDP-43Tg/+ mice increased average lifespan by 40% |
Elevated levels of cGAMP detected in the spinal cords of ALS patients |
Administration of small-molecule STING inhibitor H-151 reduced cortical and spinal cord proinflammatory cytokine gene expression and reduced neurodegeneration in ALS mice. Death of ALS patient iPSC -derived motor neurons was prevented following H-151 administration |
Yu et al., 2020 |